These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155 [TBL] [Abstract][Full Text] [Related]
3. Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake Schueffl H; Theiner S; Hermann G; Mayr J; Fronik P; Groza D; van Schonhooven S; Galvez L; Sommerfeld NS; Schintlmeister A; Reipert S; Wagner M; Mader RM; Koellensperger G; Keppler BK; Berger W; Kowol CR; Legin A; Heffeter P Chem Sci; 2021 Oct; 12(38):12587-12599. PubMed ID: 34703544 [TBL] [Abstract][Full Text] [Related]
4. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Mistry P; Loh SY; Kelland LR; Harrap KR Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583 [TBL] [Abstract][Full Text] [Related]
5. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051 [TBL] [Abstract][Full Text] [Related]
6. Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione. Mayer RD; Maines MD Biochem Pharmacol; 1990 May; 39(10):1565-71. PubMed ID: 2337413 [TBL] [Abstract][Full Text] [Related]
7. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery. Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944 [TBL] [Abstract][Full Text] [Related]
8. Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination. Rao Z; Xia Y; Jia Q; Zhu Y; Wang L; Liu G; Liu X; Yang P; Ning P; Zhang R; Zhang X; Qiao C; Wang Z J Nanobiotechnology; 2023 Aug; 21(1):265. PubMed ID: 37563614 [TBL] [Abstract][Full Text] [Related]
9. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748 [TBL] [Abstract][Full Text] [Related]
10. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma. Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561 [TBL] [Abstract][Full Text] [Related]
11. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells. Lee HM; Kim DH; Lee HL; Cha B; Kang DH; Jeong YI Arch Pharm Res; 2019 Nov; 42(11):990-999. PubMed ID: 31482490 [TBL] [Abstract][Full Text] [Related]
13. Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Rappa G; Gamcsik MP; Mitina RL; Baum C; Fodstad O; Lorico A Eur J Cancer; 2003 Jan; 39(1):120-8. PubMed ID: 12504668 [TBL] [Abstract][Full Text] [Related]
14. Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors. Nishizawa S; Araki H; Ishikawa Y; Kitazawa S; Hata A; Soga T; Hara T Oncol Lett; 2018 Jun; 15(6):8735-8743. PubMed ID: 29928324 [TBL] [Abstract][Full Text] [Related]
15. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Kramer RA; Greene K; Ahmad S; Vistica DT Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359 [TBL] [Abstract][Full Text] [Related]
17. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339 [TBL] [Abstract][Full Text] [Related]